Ann: ANR host TAVR KOL Symposium moderated by Credit Suisse, page-11

Those on the medical advisory board and KOL would not lightly put their reputations/credibility on the line.

That said what of those on the medical advisory board and KOLs that Edwards, Medtronics and co have?

Which group has the most clout/influence?, you would have to say the latter does, AVR has the ‘shackles’ of being capital ‘poor’ and going against mammoth companies that have ‘first movers’ advantage.

Ability for AVR to ‘sell’ itself will be evident soon enough (22 weeks arguably), a deal North of 40 million should see AVR on its way.

Shame AVR has never ever raised funds like APT just did, a robust sp goes a long way when implementing a CR.